EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis

Alison R McClean iD, Lucy Cheng, Nick Bansback, Fiona Clement, Mina Tadrous, Mark Harrison, Michael R Law

Arthritis Care & Research · 2023

DOI: 10.1002/acr.25099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2023. Verfasst von Alison R McClean und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Spondylitis, Ankylosing, Arthritis, Psoriatic, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Uptake of biosimilars has been suboptimal in North America. This study was undertaken to quantify the impact of various policy interventions (namely, new start and switching policies) on uptake and spending on biosimilar infliximab and etanercept in British Columbia (BC), Canada.

Methods

We used administrative claims data to identify BC residents ≥18 years of age with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and/or plaque psoriasis who qualified for public drug coverage from January 2013 to November 2020. Using interrupted time series analysis, we studied the change in proportion spent on and prescriptions dispensed of biosimilar infliximab and etanercept out of the total amount per agent after new start and biosimilar switching policies were implemented.

Results

Our study included 208,984 individuals living with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and/or psoriatic arthritis, corresponding to 5,884 patients taking infliximab and etanercept. After the new start policy, we detected a small gradual increase in the proportion of dispensed biosimilar etanercept prescriptions of 0.65% per month (95% confidence interval [95% CI] 0.44, 0.85). The trend related to the proportion of total spending on biosimilar etanercept also increased (0.51% [95% CI 0.28, 0.73]). After the switching policy, there was a sustained increase in the proportion of dispensed biosimilar etanercept and infliximab prescriptions of 76.98% (95% CI 75.56, 78.41) and 58.43% (95% CI 52.11, 64.75), respectively. Similarly, there was a persistent increase in monthly spending on biosimilar etanercept and infliximab of 78.22% (95% CI 76.65, 79.79) and 71.23% (95% CI 66.82, 75.65), respectively.

Conclusion

We found that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsSpondylitis, AnkylosingArthritis, PsoriaticAntirheumatic AgentsArthritis, RheumatoidPsoriasisHumansEtanerceptInfliximabInterrupted Time Series AnalysisBritish Columbia

Substanzen

EtanerceptInfliximabBiosimilar PharmaceuticalsAntirheumatic Agents

Autor:innen und Institutionen

  • University of British Columbia, Vancouver, British Columbia, Canada.
  • University of Calgary, Calgary, Alberta, Canada.
  • University of Toronto and Women's College Hospital, Toronto, Ontario, Canada.

ORCID-Profile: Alison R McClean

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Canada Research Chairs

Zitieren

APA

McClean, A. R., Cheng, L., Bansback, N., Clement, F., Tadrous, M., Harrison, M., & Law, M. R. (2023). Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis. Arthritis Care & Research. https://doi.org/10.1002/acr.25099

Vancouver

McClean AR, Cheng L, Bansback N, Clement F, Tadrous M, Harrison M, et al. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis. Arthritis Care & Research. 2023. doi:10.1002/acr.25099

BibTeX
@article{McClean2023,
  author = {McClean, Alison R and Cheng, Lucy and Bansback, Nick and Clement, Fiona and Tadrous, Mina and Harrison, Mark and Law, Michael R},
  title = {Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis},
  journal = {Arthritis Care & Research},
  year = {2023},
  doi = {10.1002/acr.25099}
}
Kostenlos starten →